SFX-01 positive update in bowel cancer models

Evgen Pharma PLC

27 February 2024

 

Evgen Pharma plc

("Evgen" or "the Company" or "the Group")

Positive update on SFX-01 on studies in bowel cancer models

Further evidence of SFX-01 activity in models of a major cancer

Alderley Park, UK - 27 February 2024: Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun at the University of Michigan, USA have observed activity of SFX-01 in models of colon cancer.

The in vitro and in vivo studies, funded by the USA National Cancer Institute and the University of Michigan will be generating data continuously throughout the project.

According to one of the lead investigators, Professor Chen of the Division of Hematology and Oncology, Department of Internal Medicine at the University of Michigan Medical School:

 "We have shown preliminary signs of anti-tumour activity of SFX-01 in organoids derived from human tumours."

Dr Huw Jones, CEO of Evgen Pharma said:

"These early data from our collaborators in the USA show encouraging evidence of activity of SFX-01 in another significant cancer. Colorectal or bowel cancer is the third most common cancer worldwide accounting for around one in ten of all cancer diagnoses and a cause of significant morbidity and mortality. We look forward to continuing to work with Prof Chen and colleagues to learn more about SFX-01 in this setting."

-Ends-

Enquiries

Evgen Pharma plc Dr Huw Jones, CEO  Toni Hänninen, CFO Dr Helen Kuhlman, CBO	[phone] [e-mail]
Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Nigel Birks (ECM)	[phone]
Instinctif Partners Melanie Toyne-Sewell / Jack Kincade	[phone] [e-mail]

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane. 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com.

 

END